It’s an exciting time to be part of the childhood cancer research community, and this interview was focused on career advice for those interested in childhood oncology and research. The availability of genomic profiling of tumors, targeted agents and the development of new immunotherapies are increasing the opportunities available to patients today. This lively discussion addresses the importance of preclinical data, predictive biomarker studies and the measurement of responses, with specific references to Dr. Wagner’s experience with studying irinotecan. Dr. Wagner also answered questions about radiomics and how this imaging trend can provide more insights for enhanced radiology reporting.
Please send questions and comments to TWiPO@solvingkidscancer.org